# PROJECT_STATE_CONTINUATION

## Current Project State

Repo: `fyz1500wr/pharma-analytical-method-lifecycle-platform`

Project status: **Foundation and first MVP knowledge layers completed**

This project has been initiated as the main repository for the **Pharmaceutical Analytical Method Lifecycle Intelligence Platform**.

The agreed direction is documented in:

- `PROJECT_DIRECTION_CALIBRATION.md`
- `PROJECT_INSTRUCTION.md`
- `README.md`

---

## Current Strategic Direction

The project should build a version-controlled, extensible, evidence-aware, AI-assisted platform for pharmaceutical analytical method lifecycle support.

The platform should support:

1. Product and analytical intent classification
2. Product-type to analytical-method mapping
3. Analytical method development support
4. Method optimization support
5. Validation protocol generation
6. Validation report generation
7. Technical context-aware analytical report review
8. Regulatory / literature / technology intelligence
9. Closed-loop knowledge feedback

---

## Important Architecture Decisions

1. Use **one main repo with multiple modules** at the beginning.
2. Do not split the Technical Context-Aware Analytical Report Review Module into a separate platform.
3. The Technical Context-Aware Analytical Report Review Module is a core child module of the lifecycle platform.
4. GitHub is the source of truth for rules, templates, evidence packs, and version-controlled logic.
5. Notion may be used as dashboard / task tracking, but not as the primary knowledge base.
6. Claude is preferred for final technical reasoning and document drafting.
7. Codex is preferred for repo implementation, schemas, workflows, tests, GitHub Actions, and MCP work.
8. GitHub Actions should be used to refresh and archive official regulatory source metadata.
9. MCP should expose curated evidence packs and repo knowledge to AI clients.
10. All outputs intended for GxP, vendor-facing, or regulatory use require human review.

---

## Completed Issues

The following initial issues have been completed:

| Issue | Title | Status |
|---:|---|---|
| #1 | Expand README into full platform overview | Completed |
| #2 | Expand biologics / recombinant protein DP release and stability method matrix | Completed |
| #3 | Create synthetic examples and schema validation samples | Completed |
| #4 | Draft validation protocol generation rules | Completed |
| #5 | Build first technical context-aware report review example | Completed |

---

## Current Repository Assets

### Core Project Documents

- `README.md`
- `PROJECT_DIRECTION_CALIBRATION.md`
- `PROJECT_INSTRUCTION.md`
- `PROJECT_STATE_CONTINUATION.md`
- `PROJECT_ROADMAP.md`

### Knowledge Base

- `knowledge_base/regulatory_source_priority_matrix.md`
- `knowledge_base/product_type_method_matrix/`
- `knowledge_base/validation_protocol_rules/`
- `knowledge_base/method_principle_cards/`
- `knowledge_base/reviewer_question_bank/`
- `knowledge_base/validation_gap_rules/`
- `knowledge_base/analytical_technology_registry/`
- `knowledge_base/evidence_packs/`

### Schemas

- `schemas/product_profile.schema.json`
- `schemas/analytical_method.schema.json`
- `schemas/evidence_source.schema.json`
- `schemas/validation_protocol.schema.json`
- `schemas/technical_context_card.schema.json`
- `schemas/analytical_report_gap_assessment.schema.json`

### Workflows and Templates

- `workflows/product_classification_workflow.md`
- `workflows/method_selection_workflow.md`
- `workflows/validation_protocol_generation_workflow.md`
- `workflows/technical_context_report_review_workflow.md`
- `templates/validation_protocol_template.md`
- `templates/technical_context_card_template.md`
- `templates/lab_report_gap_assessment_template.md`

### GitHub Actions

- `.github/workflows/schema_validation.yml`
- `.github/workflows/sample_schema_validation.yml`

### Examples

- `examples/schema_samples/`
- `examples/technical_context_review/`

---

## Initial MVP Direction

Initial MVP should prioritize:

```text
biologics / recombinant proteins / drug product release and stability
```

But all schemas, workflows, and knowledge base entries must remain extensible to:

- small molecules
- peptides
- monoclonal antibodies
- ADCs
- oligonucleotides
- vaccines
- cell and gene therapies
- complex formulations

---

## Current Open Issues

As of this update, the open issues are:

| Issue | Title | Recommended Treatment |
|---:|---|---|
| #6 | Phase 2 follow-up: Implement validation protocol generation engine | Keep; recommended next implementation issue |
| #7 | Phase 2 follow-up: Add validation protocol rule tests | Keep; useful after #6 or alongside engine work |
| #8 | Phase 2 follow-up: Create validation protocol markdown generator | Keep; can follow #6 |
| #9 | Phase 2 follow-up: Review validation protocol rules with SME | Keep; human review checkpoint |
| #10 | Phase 2 follow-up: Map validation protocol rules to report review gaps | Keep; supports feedback loop and report review integration |

The previously accidental issue noise was cleaned up:

- `#11` was closed as not planned.
- `#12`–`#19` were closed.

---

## GitHub Actions / CI Health Note

The repository contains schema validation workflows for JSON schema syntax and synthetic sample validation.

During the health check, the GitHub connector did not return usable workflow run or status check data for the relevant commits. This means CI status could not be independently confirmed from the connector in this session.

This should be manually checked in the GitHub Actions tab or verified in a later task using an available workflow-run query method.

---

## Recommended Next Work Items

Recommended next sequence:

1. Manually confirm GitHub Actions status for schema and sample validation.
2. Start Issue #6: implement the first code-assisted validation protocol generation engine.
3. Use structured rules from `knowledge_base/validation_protocol_rules/`.
4. Generate draft JSON aligned with `schemas/validation_protocol.schema.json`.
5. Later connect the generator to markdown output and tests.

---

## Direction Calibration Reminder

Before future work, ask:

- Does this support the analytical method lifecycle?
- Does this preserve extensibility beyond recombinant protein MVP?
- Does this separate official evidence from AI inference?
- Does this include human review gates?
- Does this strengthen product-method mapping, method development, validation, report review, regulatory intelligence, or feedback learning?

If not, the work may be outside current project direction.
